Get notified when SNTI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRisk Profile Improvements
- Material Weakness (improved) — Previously disclosed material weakness in finance and accounting resources was remediated during Q2 2025; controls now effective.
SNTI cash drops 66% to $16M; may halt ops by Q2 2026; GeneFab defaults, repays in services
Filed March 27, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 20, 2025 · ~1 min read
Key Changes
-
high
Cash declined from $48.3M to $16.4M (66% drop); management warns operations may cease by Q2 2026 without new funding. Net loss rose to $61.4M from $52.8M despite cost cuts.
MD&A: Liquidity verify on EDGAR → -
high
GeneFab (manufacturing partner) defaulted on $1.7M rent; cure involves in-kind repayment via manufacturing credits rather than cash, worsening liquidity. Company also defaulted on Alameda lease, cured by halving footprint and $2M letter-of-credit draw.
MD&A: GeneFab Default verify on EDGAR → -
high
SENTI-202 received FDA Orphan Drug and RMAT designations; Phase 1 data expanded to 20 patients showing 50% response rate, 42% complete remission, 7.6-month median duration.
Business: SENTI-202 verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (PXED 10-Q) is open in full — no account needed.
Partner
Trade SNTI commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify